Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
B7-H4
immune checkpoint inhibitors
immunohistochemistry
nivolumab
non-small-cell lung cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
01 Oct 2019
01 Oct 2019
Historique:
received:
16
09
2019
accepted:
24
09
2019
entrez:
5
10
2019
pubmed:
5
10
2019
medline:
5
10
2019
Statut:
epublish
Résumé
Reliable predictors of benefit from immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are still limited. We aimed to evaluate the association between the expression of selected molecules involved in immune response and clinical outcomes in NSCLC patients receiving nivolumab. In our study, the outcomes of 46 NSCLC patients treated with nivolumab in second or subsequent lines (Nivolumab Cohort) were compared with the expression of PD-L1, PD-L2, PD-1, B7-H3, and B7-H4 assessed by immunohistochemistry (IHC). Samples from 17 patients (37.0%) in the Nivolumab Cohort were positive for B7-H4 expression. At univariate analyses, only B7-H4 expression was associated with significantly decreased progression-free survival (PFS; 1.7 vs. 2.0 months;
Identifiants
pubmed: 31581482
pii: jcm8101566
doi: 10.3390/jcm8101566
pmc: PMC6832616
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2017 Jan 10;8(2):2171-2186
pubmed: 27974689
J Thorac Oncol. 2016 Nov;11(11):1863-1868
pubmed: 27664534
Front Oncol. 2017 Apr 06;7:67
pubmed: 28428947
J Immunother Cancer. 2016 Aug 16;4:48
pubmed: 27532023
Eur J Immunol. 2009 Jul;39(7):1754-64
pubmed: 19544488
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-9
pubmed: 26317305
Hum Immunol. 2014 Dec;75(12):1203-9
pubmed: 25446402
Nat Immunol. 2001 Mar;2(3):269-74
pubmed: 11224528
Clin Dev Immunol. 2011;2011:695834
pubmed: 22013483
Cancer Res. 2007 Sep 15;67(18):8900-5
pubmed: 17875732
J Immunol. 2003 Nov 1;171(9):4650-4
pubmed: 14568939
Oncotarget. 2016 Dec 6;7(49):81750-81756
pubmed: 27835582
J Exp Med. 2014 May 5;211(5):943-59
pubmed: 24752301
Acta Histochem. 2014 Sep;116(7):1163-8
pubmed: 25053455
Cell Physiol Biochem. 2016;39(4):1568-80
pubmed: 27626927
Oncotarget. 2016 Nov 22;7(47):76523-76533
pubmed: 27058425
Oncol Lett. 2016 Mar;11(3):1841-1846
pubmed: 26998087
Clin Cancer Res. 2017 Sep 1;23(17):5202-5209
pubmed: 28539467
Br J Cancer. 2017 Jan 3;116(1):36-43
pubmed: 27898657
Arch Pathol Lab Med. 2016 Apr;140(4):326-31
pubmed: 26756647
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5271-9
pubmed: 17875755
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Oncotarget. 2017 Apr 18;8(16):27137-27144
pubmed: 28404927
Monoclon Antib Immunodiagn Immunother. 2013 Dec;32(6):395-8
pubmed: 24328742
Lung Cancer. 2017 Jan;103:44-51
pubmed: 28024695
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Nat Immunol. 2001 Mar;2(3):261-8
pubmed: 11224527
Drug Discov Today. 2017 Aug;22(8):1266-1273
pubmed: 28600190
Oncotarget. 2017 Oct 4;8(52):90123-90131
pubmed: 29163815
Gynecol Oncol. 2014 Jul;134(1):181-189
pubmed: 24657487
J Immunol. 2004 Aug 15;173(4):2500-6
pubmed: 15294965
Oncotarget. 2016 Nov 1;7(44):72242-72249
pubmed: 27750217